Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tPA and dornase in children with empyema
NCT01862458Phase 3Withdrawn
- Sponsor
- Children's Mercy Kansas City
- Start
- Jan 2016
- Primary completion
- Jan 2016
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dornase alfa in empyema, sponsored by Children's Mercy Kansas City. Primary endpoint: Length of hospitalization after initiation of treatment at 3 weeks. Planned start Jan 2016; status: withdrawn.
02
Drugs
dornase alfa
03
Conditions
empyema
Beyond the preview
Go deeper on NCT01862458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862458.